[go: up one dir, main page]

PE20140864A1 - COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR - Google Patents

COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR

Info

Publication number
PE20140864A1
PE20140864A1 PE2013001553A PE2013001553A PE20140864A1 PE 20140864 A1 PE20140864 A1 PE 20140864A1 PE 2013001553 A PE2013001553 A PE 2013001553A PE 2013001553 A PE2013001553 A PE 2013001553A PE 20140864 A1 PE20140864 A1 PE 20140864A1
Authority
PE
Peru
Prior art keywords
quinolin
imidazo
pi3k
compound
mtor inhibitor
Prior art date
Application number
PE2013001553A
Other languages
English (en)
Inventor
David Anthony Barda
Mary Margaret Mader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20140864A1 publication Critical patent/PE20140864A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL COMPUESTO 8-[5-(1-HIDROXI-1-METILETIL)PIRIDIN-3-IL]-1-[(2S)-2-METOXIPROPIL]-3-METIL-1, 3-DIHIDRO-2H-IMIDAZO [4, 5-C]QUINOLIN-2-ONA, O UNA SAL DEL MISMO. REFERIDO TAMBIEN A UNA FORMA CRISTALINA Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL PARA EL TRATAMIENTO DE CANCER DE VEJIGA, CANCER PANCREATICO, CANCER RENAL, MELANOMA, SARCOMA
PE2013001553A 2011-01-14 2012-01-11 COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR PE20140864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
PE20140864A1 true PE20140864A1 (es) 2014-07-19

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001553A PE20140864A1 (es) 2011-01-14 2012-01-11 COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR

Country Status (39)

Country Link
US (2) US8440829B2 (es)
EP (1) EP2663564B1 (es)
JP (1) JP5891247B2 (es)
KR (1) KR101561360B1 (es)
CN (1) CN103282364B (es)
AR (1) AR084551A1 (es)
AU (1) AU2012205619B2 (es)
BR (1) BR112013017672A2 (es)
CA (1) CA2824760C (es)
CL (1) CL2013002005A1 (es)
CO (1) CO6731133A2 (es)
CR (1) CR20130289A (es)
CY (1) CY1116007T1 (es)
DK (1) DK2663564T3 (es)
DO (1) DOP2013000158A (es)
EA (1) EA022163B1 (es)
EC (1) ECSP13012764A (es)
ES (1) ES2531891T3 (es)
GT (1) GT201300180A (es)
HR (1) HRP20150135T1 (es)
HU (1) HUE024426T2 (es)
IL (1) IL227165A (es)
JO (1) JO3003B1 (es)
ME (1) ME02019B (es)
MX (1) MX2013008185A (es)
MY (1) MY164705A (es)
PE (1) PE20140864A1 (es)
PH (1) PH12013501493A1 (es)
PL (1) PL2663564T3 (es)
PT (1) PT2663564E (es)
RS (1) RS53828B1 (es)
SG (1) SG191744A1 (es)
SI (1) SI2663564T1 (es)
SV (1) SV2013004496A (es)
TN (1) TN2013000237A1 (es)
TW (1) TWI518086B (es)
UA (1) UA109921C2 (es)
WO (1) WO2012097039A1 (es)
ZA (1) ZA201304757B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
KR20180081580A (ko) * 2015-12-15 2018-07-16 일라이 릴리 앤드 캄파니 암에 대한 조합 요법
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
CN109310685B (zh) * 2016-04-12 2021-10-29 伊莱利利公司 用于治疗癌症的notch和pi3k/mtor抑制剂的组合疗法
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) * 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
ES2949364T3 (es) 2017-02-17 2023-09-28 Fred Hutchinson Cancer Center Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA
US12193994B2 (en) 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP4302827A3 (en) 2018-06-15 2024-03-13 JANSSEN Pharmaceutica NV Rapamycin analogs and uses thereof
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.
WO2022060377A1 (en) * 2020-09-21 2022-03-24 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
JP2025500409A (ja) 2021-12-22 2025-01-09 キャンプ４ セラピューティクス コーポレイション 調節ｒｎａを標的とするアンチセンスオリゴヌクレオチドを用いた遺伝子転写の調節方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
AU2006216798A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2628131C (en) 2005-11-04 2012-03-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
CA2735932C (en) * 2008-09-30 2013-07-09 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
KR101445458B1 (ko) 2009-06-04 2014-10-07 노파르티스 아게 １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체
EP2438063A1 (en) 2009-06-04 2012-04-11 Novartis AG 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases
JP2012532187A (ja) * 2009-06-30 2012-12-13 ピラマル・ライフ・サイエンシーズ・リミテッド イミダゾ［４，５−ｃ］キノリン誘導体ならびに腫瘍および／または炎症の治療におけるそれらの使用
WO2012077031A1 (en) * 2010-12-06 2012-06-14 Piramal Life Sciences Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
CO6731133A2 (es) 2013-08-15
CN103282364B (zh) 2015-06-17
EP2663564B1 (en) 2014-12-17
TN2013000237A1 (en) 2014-11-10
RS53828B1 (sr) 2015-06-30
US8658668B2 (en) 2014-02-25
EA022163B1 (ru) 2015-11-30
DOP2013000158A (es) 2013-11-30
ZA201304757B (en) 2014-12-23
UA109921C2 (uk) 2015-10-26
EA201390823A1 (ru) 2013-12-30
IL227165A (en) 2016-06-30
CA2824760A1 (en) 2012-07-19
PH12013501493A1 (en) 2021-06-02
DK2663564T3 (en) 2015-01-12
WO2012097039A1 (en) 2012-07-19
BR112013017672A2 (pt) 2018-09-18
KR101561360B1 (ko) 2015-10-16
TWI518086B (zh) 2016-01-21
MY164705A (en) 2018-01-30
PT2663564E (pt) 2015-02-24
MX2013008185A (es) 2013-08-21
CL2013002005A1 (es) 2013-12-27
CR20130289A (es) 2013-10-07
HUE024426T2 (en) 2016-01-28
HK1188454A1 (en) 2014-05-02
GT201300180A (es) 2014-04-08
ECSP13012764A (es) 2013-09-30
CY1116007T1 (el) 2017-01-25
CA2824760C (en) 2016-03-15
SV2013004496A (es) 2017-11-07
JO3003B1 (ar) 2016-09-05
HRP20150135T1 (xx) 2015-03-13
AU2012205619A1 (en) 2013-06-27
NZ611541A (en) 2015-02-27
AR084551A1 (es) 2013-05-22
KR20130116302A (ko) 2013-10-23
JP5891247B2 (ja) 2016-03-22
SG191744A1 (en) 2013-08-30
US20130237562A1 (en) 2013-09-12
ES2531891T3 (es) 2015-03-20
CN103282364A (zh) 2013-09-04
SI2663564T1 (sl) 2015-01-30
ME02019B (me) 2015-05-20
EP2663564A1 (en) 2013-11-20
AU2012205619B2 (en) 2015-05-21
JP2014502638A (ja) 2014-02-03
US8440829B2 (en) 2013-05-14
TW201307343A (zh) 2013-02-16
US20120184577A1 (en) 2012-07-19
PL2663564T3 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
PE20140864A1 (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA COMO INHIBIDOR DE PI3K/mTOR
ECSP15029636A (es) Nuevos compuestos bicíclicos y su uso como agentes antibacterianos e inhibidores de beta-lactamasa
ECSP11011258A (es) Pirimidinas fusionadas
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EP4233869A3 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CL2016001537A1 (es) Inhibidores de syk
AR089993A1 (es) Macrociclos peptidomimeticos
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
PE20190973A1 (es) Compuestos de tetrahidropirazolopirimidina
CL2016000241A1 (es) Formulación de inhibidores de la syk.
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
MX2015013711A (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selecticos de receptor de nk-3, composicion farmaceutica y metodos para su uso en trastornos mediados por el receptor de nk-3.
CR20140034A (es) Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1e inhibidores de mek
GT201400196A (es) Compuestos de heterociclilo
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EP4647076A3 (en) Therapeutically active compounds and their methods of use
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
CR20130539A (es) Triazolopiridinas
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
CR20150245A (es) Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer
NI201100155A (es) Composiciones y métodos para el tratamiento prolongado con aminopiridinas

Legal Events

Date Code Title Description
FG Grant, registration